Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2019

Open Access 01-12-2019 | Xanthine Alkaloid | Research article

Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: downregulation of xanthine oxidase and urate transporter 1

Authors: Dool-Ri Oh, Jong Ro Kim, Chul Yung Choi, Chan-hun Choi, Chang-su Na, Bok Yun Kang, Seon-Jong Kim, Young Ran Kim

Published in: BMC Complementary Medicine and Therapies | Issue 1/2019

Login to get access

Abstract

Background

ChondroT, a new herbal medication, consists of the water extracts of Osterici Radix, Lonicerae Folium, Angelicae Gigantis Radix, Clematidis Radix, and Phellodendri Cortex (6:4:4:4:3). We previously reported that ChondroT showed significant anti-arthritis and anti-inflammatory effects.

Methods

This study was designed to evaluate the effect of ChondroT on hyperuricemia. First, the effect of ChondroT was evaluated on xanthine oxidase (XOD) activity in vitro. The anti-hyperuricemic effect of ChondroT was also studied in potassium oxonate (PO)-induced hyperuricemic model mice. Uric acid (UA) and XOD were evaluated in the serum, urine, and liver of the mice. In addition, we measured serum creatinine (Cr) and blood urea nitrogen (BUN) levels as well as mRNA expression of the mouse urate transporter 1 (mURAT1) to evaluate kidney function and urate excretion in hyperuricemic mice.

Results

ChondroT showed in vitro XOD inhibitory activity in a dose-dependent manner (P < 0.05). We demonstrated that ChondroT (37.5, 75 and 150 mg/kg) significantly reduced serum UA (P < 0.01 and P < 0.001, respectively), and upregulated urinary UA (P < 0.001, respectively) in PO-induced hyperuricemic mice. In addition, ChondroT (75 and 150 mg/kg) significantly reduced Cr (P < 0.05 and P < 0.01, respectively), BUN (P < 0.05 and P < 0.001, respectively), GOT (P < 0.05 and P < 0.01, respectively), and GPT (P > 0.05 and P < 0.05, respectively) levels in PO-induced hyperuricemic mice. ChondroT (75 and 150 mg/kg) also significantly downregulated serum (P < 0.05) and liver (P < 0.05) XOD activity. Compared to the hyperuricemic mice, the ChondroT (37.5, 75, and 150 mg/kg)-treated mice showed decreased mURAT1 protein expression level.

Conclusion

ChondroT displayed anti-hyperuricemic effects by regulating XOD activity and kidney mURAT1.
Literature
1.
Haidari F, Rashidi MR, Keshavarz SA, Mahboob SA, Eshraghian MR, Shahi MM. Effects of onion on serum uric acid levels and hepatic xanthine dehydrogenase/xanthine oxidase activities in hyperuricemic rats. Pak J Biol Sci. 2008;11(14):1779–84.CrossRef
2.
Chen JHCS, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009;61:225–32.CrossRef
3.
Graessler J, Graessler A, Unger S, Kopprasch S, Tausche AK, Kuhlisch E, Schroeder HE. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum. 2006;54(1):292–300.CrossRef
4.
Vazquez-Mellado J, Jimenez-Vaca AL, Cuevas-Covarrubias S, Alvarado-Romano V, Pozo-Molina G, Burgos-Vargas R. Molecular analysis of the SLC22A12 (URAT1) gene in patients with primary gout. Rheumatology. 2007;46(2):215–9.CrossRef
5.
Umamaheswari M, Asokkumar K, Sivashanmugam AT, Remyaraju A, Subhadradevi V, Ravi TK. In vitro xanthine oxidase inhibitory activity of the fractions of Erythrina stricta Roxb. J Ethnopharmacol. 2009;124(3):646–8.CrossRef
6.
Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther. 2006;8(Suppl 1):S3.CrossRef
7.
Kim YH, Lee JH. CheongKangEuiGam. Seoul: Seongbosa; 2001. p. 315.
8.
Jeoung BR, Lee KD, Na CS, Kim YE, Kim B, Kim YR. Ganghwaljetongyeum, an anti-arthritic remedy, attenuates synoviocyte proliferation and reduces the production of proinflammatory mediators in macrophages: the therapeutic effect of GHJTY on rheumatoid arthritis. BMC Complemen Altern Med. 2013;13:47.CrossRef
9.
Choi W, Choi CH, Kim YR, Kim SJ, Na CS, Lee H. HerDing: herb recommendation system to treat diseases using genes and chemicals. Database (Oxford). 2016;2016:1–7.
10.
Park JU, Kim SJ, Na CS, Choi CH, Seo CS, Son JK, Kang BY, Kim YR. Chondroprotective and anti-inflammatory effects of ChondroT, a new complex herbal medication. BMC Complem Altern Med. 2016;16:213.CrossRef
11.
Sun Y, Brenner H, Sauerland S, Gunther KP, Puhl W, Sturmer T. Serum uric acid and patterns of radiographic osteoarthritis--the Ulm osteoarthritis study. Scand J Rheumatol. 2000;29(6):380–6.CrossRef
12.
Acheson RM, Collart AB. New Haven survey of joint diseases. XVII. Relationship between some systemic characteristics and osteoarthrosis in a general population. Ann Rheum Dis. 1975;34(5):379–87.CrossRef
13.
Denoble AEHK, Stabler TV, Kelly SJ, Hershfield MS, McDaniel GE, Coleman RE, Kraus VB. Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci U S A. 2011;108:2088–93.CrossRef
14.
Nowatzky J, Howard R, Pillinger MH, Krasnokutsky S. The role of uric acid and other crystals in osteoarthritis. Curr Rheumatol Rep. 2010;12(2):142–8.CrossRef
15.
Wang SY, Yang CW, Liao JW, Zhen WW, Chu FH, Chang ST. Essential oil from leaves of Cinnamomum osmophloeum acts as a xanthine oxidase inhibitor and reduces the serum uric acid levels in oxonate-induced mice. Phytomedicine. 2008;15:940–5.CrossRef
16.
Stavric B, Clayman S, Gradd RE, Hebert D. Some in vivo effects in the rat induced by chlorprothixene and potassium oxonate. Pharmacol Res Commun. 1975;7:117–24.CrossRef
17.
Hall IH, Scoville JP, Reynolds DJ, Simlot R, Duncan P. Substituted cyclic imides as potential anti-gout agents. Life Sci. 1990;46:1923–7.CrossRef
18.
Wang X, Wang C, Hu Q, Lv Y, Zhang X, Ouyang Z, Kong L. The dual actions of Sanmiao wan as a hypouricemic agent: Down-regulation of hepatic XOD and renal mURAT1 in hyperuricemic mice. J Ethnopharmacol. 2010;128(1):107–15.CrossRef
19.
Mohammadi A, Mirzaei F, Jamshidi M, Yari R, Pak S, Norouzian P, Abdolkarimi V, Oshaghi EA. Influence of flaxseed on lipid profiles and expression of LXRα, in intestine of diabetic rat. Int J Biol. 2013;5(4):23-8.
20.
Mohammadi A, Vafaei SA, Moradi MN, Ahmadi M, Pourjafar M, Oshaghi EA. Combination of ezetimibe and garlic reduces serum lipids and intestinal Niemann-pick C1-like 1 expression more effectively in Hypercholesterolemic mice. Avicenna J Med Biochem. 2015;3(1):e23205.
21.
Elion GB, Kovensky A, Hitchings GH. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol. 1966;15(7):863–80.CrossRef
22.
Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005;76(16):1835–47.CrossRef
23.
Bisht M, Bist SS. Febuxostat: a novel agent for management of hyperuricemia in gout. Indian J Pharm Sci. 2011;73(6):597–600.CrossRef
24.
Hoffmann D, Fuchs TC, Henzler T, Matheis KA, Herget T, Dekant W, Hewitt P, Mally A. Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity. Toxicology. 2010;277(1–3):49–58.CrossRef
25.
Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ. A role for uric acid in the progression of renal disease. J Am Soci Nephrol. 2002;13(12):2888–97.CrossRef
26.
Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51–9.CrossRef
27.
Tomita M, Mizuno S, Yamanaka H, Hosoda Y, Sakuma K, Matuoka Y, Odaka M, Yamaguchi M, Yosida H, Morisawa H, et al. Does hyperuricemia aeffect mortality? A prospective cohort study of japanese male workers. J Epidemiol. 2000;10:403–9.CrossRef
28.
29.
Kong LD, Yang C, Ge F, Wang HD, Guo YS. A Chinese herbal medicine Ermiao wan reduces serum uric acid level and inhibits liver xanthine dehydrogenase and xanthine oxidase in mice. J Ethnopharmacol. 2004;93(2–3):325–30.CrossRef
30.
Kim JH, Huh JE, Baek YH, Lee JD, Choi DY, Park DS. Effect of Phellodendron amurense in protecting human osteoarthritic cartilage and chondrocytes. J Ethnopharmacol. 2011;134(2):234–42.CrossRef
31.
Shin YJ, Hwang JM, Lee SC. Antioxidant and xanthine oxidase inhibitory activities of hot water extracts of medicinal herbs. J Korean Soc Food Sci Nutr. 2013;42(10):1712–6.CrossRef
32.
Lee JS, Kim KH, Lee SD, Kim KS. The effect of Clematidis Radix herbal-acupuncture solution, on collagen, adjuvant, lipopolysaccharide and phospholipase A2 induced rheumatoid arthritis in mice. J Korean Acupunct Moxibustion Society. 2012;29(1):127–37.
33.
Meng ZQ, Tang ZH, Yan YX, Guo CR, Cao L, Ding G, Huang WZ, Wang ZZ, Wang KD, Xiao W, et al. Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation. Am J Chin Med. 2014;42(6):1471–83.CrossRef
34.
Ahmad I, Ijaz F, Fatima I, Ahmad N, Chen S, Afza N, Malik A. Xanthine oxidase/tyrosinase inhibiting, antioxidant, and antifungal oxindole alkaloids from Isatis costata. Pharm Biol. 2010;48(6):716–21.CrossRef
Metadata
Title
Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: downregulation of xanthine oxidase and urate transporter 1
Authors
Dool-Ri Oh
Jong Ro Kim
Chul Yung Choi
Chan-hun Choi
Chang-su Na
Bok Yun Kang
Seon-Jong Kim
Young Ran Kim
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2019
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-018-2415-2

Other articles of this Issue 1/2019

BMC Complementary Medicine and Therapies 1/2019 Go to the issue

Research article

Water-soluble polyphenol-rich clove extract lowers pre- and post-prandial blood glucose levels in healthy and prediabetic volunteers: an open label pilot study

Research article

Effect of freeze-dried Carica papaya leaf juice on inflammatory cytokines production during dengue virus infection in AG129 mice

Research article

Potential in vitro anti-allergic, anti-inflammatory and cytotoxic activities of ethanolic extract of Baliospermum montanum root, its major components and a validated HPLC method

Research article

‘We are nothing without herbs’: a story of herbal remedies use during pregnancy in rural Ghana

Research article

Variation in the metabolites and α-glucosidase inhibitory activity of Cosmos caudatus at different growth stages

Research article

Effects of unaltered and bioconverted mulberry leaf extracts on cellular glucose uptake and antidiabetic action in animals